These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 22781621)

  • 1. [Tumor necrosis factor-α targeted therapy for graft verous host disease].
    Zhao XY; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):243-6. PubMed ID: 22781621
    [No Abstract]   [Full Text] [Related]  

  • 2. Etanercept in graft-versus-host disease.
    Andolina M; Rabusin M; Maximova N; Di Leo G
    Bone Marrow Transplant; 2000 Oct; 26(8):929. PubMed ID: 11081399
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment with thalidomide and production of tumor necrosis factor alpha].
    Pizarro A; Pinilla J; García-Tobaruela A
    Med Clin (Barc); 1993 Jun; 101(4):158. PubMed ID: 8355553
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute graft-versus-host disease after liver transplant: novel use of etanercept and the role of tumor necrosis factor alpha inhibitors.
    Thin L; Macquillan G; Adams L; Garas G; Seow C; Cannell P; Augustson B; Mitchell A; Delriveire L; Jeffrey G
    Liver Transpl; 2009 Apr; 15(4):421-6. PubMed ID: 19326415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Life-threatening acute pancreatitis due to thalidomide therapy for chronic graft-versus-host disease.
    Chung LW; Yeh SP; Hsieh CY; Liao YM; Huang HH; Lin CY; Chiu CF
    Ann Hematol; 2008 May; 87(5):421-3. PubMed ID: 18040684
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful response to infliximab of recurrent pericardial graft versus host disease in a pediatric patient.
    Rubio PM; Labrandero C; Riesco S; Plaza D; González B; Muñoz GM; Sastre A
    Bone Marrow Transplant; 2013 Jan; 48(1):144-5. PubMed ID: 22580769
    [No Abstract]   [Full Text] [Related]  

  • 7. TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies.
    Tsimberidou AM; Giles FJ
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):277-86. PubMed ID: 12113051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thalidomide--a new prospective therapy in rheumatology and transplantation].
    Pałgan K; Pałgan I; Dziedziczko A
    Wiad Lek; 2003; 56(11-12):574-6. PubMed ID: 15058168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention and treatment of acute GvHD.
    Messina C; Faraci M; de Fazio V; Dini G; Calò MP; Calore E;
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S65-70. PubMed ID: 18545247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel strategies for the treatment and diagnosis of graft-versus-host-disease.
    Ferrara JL
    Best Pract Res Clin Haematol; 2007 Mar; 20(1):91-7. PubMed ID: 17336259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab treatment for steroid-refractory acute graft-versus-host disease after orthotopic liver transplantation: a case report.
    Piton G; Larosa F; Minello A; Becker MC; Mantion G; Aubin F; Deconinck E; Hillon P; Di Martino V
    Liver Transpl; 2009 Jul; 15(7):682-5. PubMed ID: 19562700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease.
    Uberti JP; Ayash L; Ratanatharathorn V; Silver S; Reynolds C; Becker M; Reddy P; Cooke KR; Yanik G; Whitfield J; Jones D; Hutchinson R; Braun T; Ferrara JL; Levine JE
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):680-7. PubMed ID: 16125638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.
    Hill GR; Teshima T; Gerbitz A; Pan L; Cooke KR; Brinson YS; Crawford JM; Ferrara JL
    J Clin Invest; 1999 Aug; 104(4):459-67. PubMed ID: 10449438
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of GVHD--TNF-antibodies and related antagonists.
    Holler E; Kolb HJ; Wilmanns W
    Bone Marrow Transplant; 1993; 12 Suppl 3():S29-31. PubMed ID: 8124254
    [No Abstract]   [Full Text] [Related]  

  • 15. [Correlation of donor and recipient serum interleukin 2 and tumor necrosis factor alpha levels to acute graft-versus-host disease in hematopoietic stem cell transplantation].
    Hua JY; Zhou XH; Pang Y; Huang RW
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Apr; 30(4):831-3. PubMed ID: 20423859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor necrosis factor-alpha associated with chronic graft-versus-host disease in bone marrow transplantation recipients.
    Fujii Y; Kaku K; Kaneko T
    Bone Marrow Transplant; 1992 Aug; 10(2):194-5. PubMed ID: 1525611
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2 R antibody.
    Hervé P; Racadot E; Wijdenes J; Flesch M; Tiberghien P; Bordigoni P; Holler E; Powles M; Bourdeau M; Wilmer E
    Bone Marrow Transplant; 1991; 7 Suppl 2():149. PubMed ID: 1878688
    [No Abstract]   [Full Text] [Related]  

  • 18. Interleukin-1 or tumor necrosis factor-alpha antagonists do not inhibit graft-versus-host disease induced across the major histocompatibility barrier in mice.
    Vallera DA; Taylor PA; Vannice JL; Panoskaltsis-Mortari A; Blazar BR
    Transplantation; 1995 Dec; 60(11):1371-4. PubMed ID: 8525541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Busca A; Locatelli F; Marmont F; Ceretto C; Falda M
    Am J Hematol; 2007 Jan; 82(1):45-52. PubMed ID: 16937391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradigm shift for graft-versus-host disease.
    Ferrara JL
    Bone Marrow Transplant; 1994 Aug; 14(2):183-4. PubMed ID: 7994229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.